GlassScriptPhysician profile
Shiv Sab
NPI 1578839106
$10,194.43
in general payments reported to CMS, 2019-2025
37 companies · $3,172 in 2025
The $3,172 reported for 2025 was more than what 76% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.08 · 2022: $952 · 2023: $2,006 · 2024: $4,037 · 2025: $3,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,943 · Travel and Lodging: $2,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,943.20 |
| Travel and Lodging | $2,271.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,122.76 | 2023-2025 | Micra, Linq II, Aurora Ev-Icd Mri Surescan |
| Cvrx, INC. | $589.83 | 2022-2025 | Barostim Neo System |
| Amgen INC. | $545.77 | 2022-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $487.82 | 2019-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Wavewriter Alpha Prime 16 |
| Aop Health US, LLC | $463.52 | 2025 | Rapiblyk |
| Kestra Medical Technology Services, INC. | $402.72 | 2024-2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $368.10 | 2022-2025 | Farxiga, Wainua, Brilinta |
| Merck Sharp & Dohme LLC | $355.34 | 2022-2025 | Verquvo |
| Esperion Therapeutics, INC. | $330.04 | 2022-2025 | Nexletol, Nexlizet |
| Heartflow, INC. | $320.75 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $316.46 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $301.66 | 2025 | Evkeeza, Praluent |
| Pfizer INC. | $260.26 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $254.12 | 2022-2025 | Lifevest |
| Abiomed | $243.94 | 2023-2025 | Impella |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $229.25 | 2022-2023 | Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Irhythm Technologies, INC. | $222.55 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.42 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $188.23 | 2022-2025 | Eliquis, Camzyos |
| Alnylam Pharmaceuticals INC. | $173.09 | 2025 | Amvuttra |
| Actelion Pharmaceuticals US, INC. | $167.73 | 2023-2024 | Uptravi, Opsumit |
| Biosense Webster, INC. | $135.05 | 2022 | |
| Novo Nordisk INC | $72.18 | 2022-2024 | Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $63.92 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $59.60 | 2022-2024 | |
| Microtransponder, INC. | $46.38 | 2025 | |
| Lantheus Medical Imaging, INC. | $45.13 | 2024 | |
| Janssen Pharmaceuticals, INC | $37.35 | 2023-2024 | Xarelto |
| Cleerly, INC. | $27.13 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Getinge USA Sales, LLC | $24.83 | 2025 | Cardiosave Rescue |
| Lexicon Pharmaceuticals, INC. | $24.70 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $24.02 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $23.47 | 2025 | |
| Atricure, INC. | $20.95 | 2022 | |
| Chiesi USA, INC. | $19.26 | 2024 | Kengreal |
| Daiichi Sankyo INC. | $18.56 | 2023 | Injectafer |
| Baxter Healthcare | $15.54 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiv Sab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.